US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% NVDA $215.38 ▼-1.17% GOOGL $324.89 ▲+1.34% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Athersys, Inc. - Common Stock (NQ:ATHX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Athersys, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Licenses its Animal Health Assets to Ardent Animal Health
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Director Jane Wasman Appointed Board Chair
From Athersys, Inc.
Via Business Wire
News headline image
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
From Athersys, Inc.
Via Business Wire
News headline image
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Host Business Update Conference Call on August 9th
From Athersys, Inc.
Via Business Wire
News headline image
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Restructures Debt with Supplier
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Participate in Three Upcoming Conferences
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
From Athersys, Inc.
Via Business Wire
News headline image
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
From Athersys, Inc.
Via Business Wire
News headline image
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Host Business Update Conference Call on April 20th
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Announces Successful Type B Meeting with the FDA
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Expands IP Protection with First New Patent for SIFU® Technology
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Host Business Update Conference Call on February 14th
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Participate in International Stroke Conference and BioProcess International
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Provides MultiStem Clinical Update
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Appoints Joseph Nolan to Its Board of Directors
From Athersys, Inc.
Via Business Wire
News headline image
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
From Athersys, Inc.
Via Business Wire
News headline image
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
From Athersys, Inc.
Via Business Wire
< Previous 1 2 3 Next >